Eli Lilly and Company (FRA:LLY)

Market Cap	600.29B
Revenue (ttm)	45.34B
Net Income (ttm)	10.28B
Shares Out	n/a
EPS (ttm)	11.37
PE Ratio	58.42
Forward PE	30.49
Dividend	5.18 (0.79%)
Ex-Dividend Date	May 16, 2025

Volume	179
Average Volume	462
Open	660.20
Previous Close	661.60
Day's Range	658.20 - 661.60
52-Week Range	616.90 - 888.80
Beta	n/a
RSI	51.51
Earnings Date	Aug 7, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD